Sivacolundhu Ramesh K, Runge Jeffrey J, Donovan Taryn A, Barber Lisa G, Saba Corey F, Clifford Craig A, de Lorimier Louis-Philippe, Atwater Stephen W, DiBernardi Lisa, Freeman Kim P, Bergman Philip J
Department of Surgery, Animal Medical Center, New York, NY 10065, USA.
J Am Vet Med Assoc. 2013 Jul 1;243(1):96-101. doi: 10.2460/javma.243.1.96.
To examine the biological behavior of ulnar osteosarcoma and evaluate predictors of survival time in dogs.
Retrospective case series.
30 dogs with primary ulnar osteosarcoma.
Medical records were reviewed. Variables recorded and examined to identify predictors of survival time were signalment, tumor location in the ulna, tumor length, serum alkaline phosphatase activity, surgery type, completeness of excision, tumor stage, tumor grade, histologic subtype, development of metastases, and use of chemotherapy.
30 cases were identified from 9 institutions. Eleven dogs were treated with partial ulnar ostectomy and 14 with amputation; in 5 dogs, a resection was not performed. Twenty-two dogs received chemotherapy. Median disease-free interval and survival time were 437 and 463 days, respectively. Negative prognostic factors for survival time determined via univariate analyses were histologic subtype and development of lung metastases. Telangiectatic or telangiectatic-mixed subtype (n = 5) was the only negative prognostic factor identified via multivariate analysis (median survival time, 208 days). Dogs with telangiectatic subtype were 6.99 times as likely to die of the disease.
The prognosis for ulnar osteosarcoma in this population was no worse and may have been better than the prognosis for dogs with osteosarcoma involving other appendicular sites. Partial ulnar ostectomy was associated with a low complication rate and good to excellent function and did not compromise survival time. Telangiectatic or telangiectatic-mixed histologic subtype was a negative prognostic factor for survival time. The efficacy of chemotherapy requires further evaluation.
研究犬尺骨骨肉瘤的生物学行为并评估生存时间的预测因素。
回顾性病例系列研究。
30只患有原发性尺骨骨肉瘤的犬。
查阅病历。记录并检查的变量包括品种、尺骨肿瘤位置、肿瘤长度、血清碱性磷酸酶活性、手术类型、切除完整性、肿瘤分期、肿瘤分级、组织学亚型、转移情况及化疗使用情况，以确定生存时间的预测因素。
从9家机构中识别出30例病例。11只犬接受了尺骨部分切除术，14只接受了截肢术；5只犬未进行切除手术。22只犬接受了化疗。无病间期和生存时间的中位数分别为437天和463天。单因素分析确定的生存时间的负面预后因素为组织学亚型和肺转移情况。毛细血管扩张型或毛细血管扩张混合型亚型（n = 5）是多因素分析中唯一确定的负面预后因素（中位生存时间为208天）。患有毛细血管扩张型亚型的犬死于该病的可能性是其他犬的6.99倍。
该群体中尺骨骨肉瘤的预后并不比涉及其他附肢部位骨肉瘤的犬更差，甚至可能更好。尺骨部分切除术的并发症发生率低，功能良好至优秀，且不影响生存时间。毛细血管扩张型或毛细血管扩张混合型组织学亚型是生存时间的负面预后因素。化疗的疗效需要进一步评估。
